Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 522

1.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

2.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
3.

One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy.

Lems WF, Baak MM, van Tuyl LH, Lodder MC, Dijkmans BA, Boers M.

RMD Open. 2016 Sep 12;2(2):e000313. doi: 10.1136/rmdopen-2016-000313. eCollection 2016.

4.

Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.

van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2016 Apr;43(4):758-64. doi: 10.3899/jrheum.150857. Epub 2016 Feb 15.

PMID:
26879348
5.

Changing phenotype of diffuse idiopathic skeletal hyperostosis over time: comment on the article by Saleem and Hawass.

Lemmers SA, Dijkmans BA, Janssen M.

Arthritis Rheumatol. 2015 Jun;67(6):1684-5. doi: 10.1002/art.39066. No abstract available.

6.

Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests.

van Weely SF, Dekker J, Steultjens MP, van Denderen JC, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2015 Apr;42(4):623-9. doi: 10.3899/jrheum.140337. Epub 2015 Jan 15.

PMID:
25593234
7.

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides.

Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, Tak PP, Posthumus MD, Wijmenga C, Huizinga T, van der Helm-van Mil AH, Stoeken-Rijsbergen G, Rodriguez-Rodriguez L, Balsa A, González-Álvaro I, González-Gay MÁ, Gómez-Vaquero C, Franke B; LifeLines Cohort Study, Vermeulen S, van der Horst-Bruinsma Ie, Dijkmans BA, Wolbink GJ, Ophoff RA, Maehlen MT, van Riel P, Merriman M, Klareskog L, Lie BA, Merriman T, Crusius JB, Brouwer E, Martin J, de Vries N, Toes R, Padyukov L, Koeleman BP.

Ann Rheum Dis. 2015 Mar;74(3):e15. doi: 10.1136/annrheumdis-2013-204591. Epub 2014 Feb 14.

PMID:
24532677
8.

Imported Armillifer pentastomiasis: report of a symptomatic infection in The Netherlands and mini-review.

Tappe D, Dijkmans AC, Brienen EA, Dijkmans BA, Ruhe IM, Netten MC, van Lieshout L.

Travel Med Infect Dis. 2014 Mar-Apr;12(2):129-33. doi: 10.1016/j.tmaid.2013.10.011. Epub 2013 Oct 31. Review.

9.

Increased progression of carotid intima media thickness in thyroid peroxidase antibodies-positive rheumatoid arthritis patients.

Raterman HG, Voskuyl AE, Simsek S, Schreurs MW, van Hoogstraten IM, Peters MJ, van Halm VP, Dijkmans BA, Lips P, Lems WF, Nurmohamed MT.

Eur J Endocrinol. 2013 Oct 21;169(6):751-7. doi: 10.1530/EJE-13-0394. Print 2013 Dec.

PMID:
24005313
10.

Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.

van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G.

Scand J Rheumatol. 2014;43(1):9-16. doi: 10.3109/03009742.2013.797490. Epub 2013 Aug 30.

PMID:
23987246
11.

What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.

van Weely SF, van Denderen JC, Steultjens MP, Nurmohamed MT, Dijkmans BA, Dekker J, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2013 Oct;52(10):1884-9. doi: 10.1093/rheumatology/ket240. Epub 2013 Jul 17.

PMID:
23864170
12.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

13.

Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.

Dirven L, Klarenbeek NB, van den Broek M, van Groenendael JH, de Sonnaville PB, Kerstens PJ, Huizinga TW, Dijkmans BA, Lems WF, Allaart CF.

Clin Rheumatol. 2013 May;32(5):585-90. doi: 10.1007/s10067-012-2136-8. Epub 2012 Dec 9.

PMID:
23224330
14.

Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF, Voskuyl AE, Bultink IE.

Osteoporos Int. 2013 Jun;24(6):1827-33. doi: 10.1007/s00198-012-2157-9. Epub 2012 Oct 3.

PMID:
23052940
15.

Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept.

van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT.

Clin Rheumatol. 2012 Dec;31(12):1677-82. doi: 10.1007/s10067-012-2072-7. Epub 2012 Sep 1.

PMID:
22941219
16.

Results of a questionnaire on the treatment of patients with Behçet's syndrome: a trend for more intensive treatment.

Turkstra F, van Vugt RM, Dijkmans BA, Yazici Y, Yazici H.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S10-3. Epub 2012 Sep 25.

PMID:
22776270
17.

High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review.

van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE.

Clin Rheumatol. 2012 Nov;31(11):1529-35. doi: 10.1007/s10067-012-2018-0. Epub 2012 Jun 16. Review.

18.

HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab.

Raterman HG, Levels H, Voskuyl AE, Lems WF, Dijkmans BA, Nurmohamed MT.

Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/annrheumdis-2011-201228. Epub 2012 May 15.

PMID:
22589377
19.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE.

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

20.

Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study.

Bruijnen ST, van der Weijden MA, Klein JP, Hoekstra OS, Boellaard R, van Denderen JC, Dijkmans BA, Voskuyl AE, van der Horst-Bruinsma IE, van der Laken CJ.

Arthritis Res Ther. 2012 Apr 2;14(2):R71. doi: 10.1186/ar3792.

21.

Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis.

van Weely SF, van Denderen JC, Steultjens MP, van der Leeden M, Nurmohamed MT, Dekker J, Dijkmans BA, van der Horst-Bruinsma IE.

Arthritis Res Ther. 2012 Mar 8;14(2):R52. doi: 10.1186/ar3765.

22.

Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies.

van der Woude D, Visser K, Klarenbeek NB, Ronday HK, Peeters AJ, Kerstens PJ, Dijkmans BA, Huizinga TW, van der Helm-van Mil AH, Allaart CF.

Rheumatology (Oxford). 2012 Jun;51(6):1120-8. doi: 10.1093/rheumatology/ker516. Epub 2012 Feb 15.

PMID:
22337939
23.

Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications.

Dijkmans AC, de Jong EP, Dijkmans BA, Lopriore E, Vossen A, Walther FJ, Oepkes D.

Curr Opin Obstet Gynecol. 2012 Mar;24(2):95-101. doi: 10.1097/GCO.0b013e3283505a9d. Review.

PMID:
22249146
24.

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.

Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.

J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. doi: 10.1124/jpet.111.187542. Epub 2012 Jan 10.

PMID:
22235146
25.

Pulmonary arterial hypertension in systemic sclerosis is associated with profound impairment of microvascular endothelium-dependent vasodilatation.

Hofstee HM, Voskuyl AE, Vonk Noordegraaf A, Smulders YM, Postmus PE, Dijkmans BA, Serné EH.

J Rheumatol. 2012 Jan;39(1):100-5. doi: 10.3899/jrheum.110397. Epub 2011 Dec 15.

PMID:
22174212
26.

Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial.

van Eijk IC, Nielen MM, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BA, van Schaardenburg D.

Rheumatology (Oxford). 2012 Apr;51(4):686-94. doi: 10.1093/rheumatology/ker355. Epub 2011 Dec 13.

27.

The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.

van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2012 Feb;71(2):245-8. doi: 10.1136/annrheumdis-2011-200379. Epub 2011 Nov 21.

PMID:
22110122
28.

Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.

Dirven L, Visser K, Klarenbeek NB, Ewals JA, Han KH, Peeters AJ, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Scand J Rheumatol. 2012 Feb;41(1):15-9. doi: 10.3109/03009742.2011.594964. Epub 2011 Nov 21.

PMID:
22103436
29.

[From splint to smart syringe: the changing perspective of rheumatology].

Dijkmans BA.

Ned Tijdschr Geneeskd. 2011;155(30-31):A3470. Review. Dutch.

PMID:
22085511
30.

Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction.

den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JW, Hoes JN, Dijkmans BA, Diamant M.

Arthritis Rheum. 2012 Mar;64(3):639-46. doi: 10.1002/art.33378.

31.

Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRÉ Study.

van Sijl AM, van den Oever IA, Peters MJ, Boers M, Dijkmans BA, van Halm VP, Smulders YM, Voskuyl AE, Nurmohamed MT.

Ann Rheum Dis. 2012 Mar;71(3):341-4. doi: 10.1136/annrheumdis-2011-200051. Epub 2011 Sep 27.

PMID:
21953344
32.

High frequency of vertebral fractures in early spondylarthropathies.

van der Weijden MA, van der Horst-Bruinsma IE, van Denderen JC, Dijkmans BA, Heymans MW, Lems WF.

Osteoporos Int. 2012 Jun;23(6):1683-90. doi: 10.1007/s00198-011-1766-z. Epub 2011 Sep 17.

PMID:
21927925
33.

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.

Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ.

Ann Rheum Dis. 2012 Jan;71(1):88-91. doi: 10.1136/annrheumdis-2011-200184. Epub 2011 Sep 12.

PMID:
21914626
34.

Changes in hand bone mineral density and the association with the level of disease activity in patients with rheumatoid arthritis: bone mineral density measurements in a multicenter randomized clinical trial.

Dirven L, Güler-Yüksel M, de Beus WM, Ronday HK, Speyer I, Huizinga TW, Dijkmans BA, Allaart CF, Lems WF.

Arthritis Care Res (Hoboken). 2011 Dec;63(12):1691-9. doi: 10.1002/acr.20612.

35.

Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study.

Gent YY, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BA, Lammertsma AA, van der Laken CJ.

Arthritis Rheum. 2012 Jan;64(1):62-6. doi: 10.1002/art.30655.

36.

Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.

Klarenbeek NB, Koevoets R, van der Heijde DM, Gerards AH, Ten Wolde S, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2011 Oct;70(10):1815-21. doi: 10.1136/ard.2010.149260. Epub 2011 Aug 3.

PMID:
21813548
37.

Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis.

van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, van Schaardenburg D.

Arthritis Rheum. 2011 Nov;63(11):3226-33. doi: 10.1002/art.30537.

38.

Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.

Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF.

BMC Musculoskelet Disord. 2011 Jul 21;12:167. doi: 10.1186/1471-2474-12-167.

39.

Effect of the application of trial inclusion criteria on the efficacy of adalimumab therapy in a rheumatoid arthritis cohort.

Visman IM, Bartelds GM, Ouwerkerk W, Ravelli AC, Peelen LM, Dijkmans BA, Boers M, Nurmohamed MT.

J Rheumatol. 2011 Sep;38(9):1884-90. doi: 10.3899/jrheum.101283. Epub 2011 Jun 15.

PMID:
21677005
40.

The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.

van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT.

Semin Arthritis Rheum. 2011 Dec;41(3):393-400. doi: 10.1016/j.semarthrit.2011.04.003. Epub 2011 Jun 12.

PMID:
21665247
41.

Simplified versions of the original disease activity score: validation in the BeSt trial.

Koevoets R, Klarenbeek NB, Güler-Yüksel M, van Oosterhout M, van Krugten MV, Kerstens PJ, Huizinga TW, Dijkmans BA, van der Heijde DM, Allaart CF.

Ann Rheum Dis. 2011 Aug;70(8):1471-4. doi: 10.1136/ard.2010.149146. Epub 2011 May 8.

PMID:
21551508
42.

Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative.

Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, de Wit M, Dijkmans BA, Dougados M, Englbrecht M, Gogus F, Heiberg T, Hernandez C, Kirwan JR, Mola EM, Cerinic MM, Otsa K, Schett G, Scholte-Voshaar M, Sokka T, von Krause G, Wells GA, Kvien TK.

Ann Rheum Dis. 2011 Jun;70(6):935-42. doi: 10.1136/ard.2010.142901.

PMID:
21540201
43.

Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.

van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans HM, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2011 Aug;70(8):1389-94. doi: 10.1136/ard.2010.147751. Epub 2011 Apr 24.

PMID:
21515916
44.

Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study.

Overbeek MJ, Boonstra A, Voskuyl AE, Vonk MC, Vonk-Noordegraaf A, van Berkel MP, Mooi WJ, Dijkmans BA, Hondema LS, Smit EF, Grünberg K.

Arthritis Res Ther. 2011 Apr 14;13(2):R61. doi: 10.1186/ar3315.

45.

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ.

JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.

PMID:
21486979
46.

Microvascular function is preserved in newly diagnosed rheumatoid arthritis and low systemic inflammatory activity.

van Eijk IC, Serné EH, Dijkmans BA, Smulders Y, Nurmohamed M.

Clin Rheumatol. 2011 Aug;30(8):1113-8. doi: 10.1007/s10067-011-1750-1. Epub 2011 Apr 13.

47.

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ.

Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209.

48.

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.

Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL.

Ann Rheum Dis. 2011 Jun;70(6):1153-9. doi: 10.1136/ard.2010.147199. Epub 2011 Mar 27.

PMID:
21444302
49.

Drug-free remission: is it already possible?

van den Broek M, Huizinga TW, Dijkmans BA, Allaart CF.

Curr Opin Rheumatol. 2011 May;23(3):266-72. doi: 10.1097/BOR.0b013e32834563e3. Review.

PMID:
21427578
50.

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2011 Jun;70(6):1039-46. doi: 10.1136/ard.2010.141234. Epub 2011 Mar 17.

PMID:
21415052

Supplemental Content

Loading ...
Support Center